Clinical outcomes of HbA1c standardisation
|
|
- Rodney Montgomery
- 5 years ago
- Views:
Transcription
1 Clinical outcomes of HbA1c standardisation Eric S. Kilpatrick Division Chief, Clinical Chemistry Sidra Medicine, Doha, Qatar Professor of Pathology & Laboratory Medicine, Weill Cornell Medicine-Qatar Honorary Professor in Clinical Biochemistry, Hull York Medical School, UK
2 HbA1c standardisation and clinical outcomes What are the clinical outcomes associated with HbA1c? How has standardisation improved the precision of outcomes? Could a HbA1c unit change worsen outcomes? Is there more to life than just HbA1c?
3 HbA1c standardisation and clinical outcomes What are the clinical outcomes associated with HbA1c? How has standardisation improved the precision of outcomes? Could a HbA1c unit change worsen outcomes? Is there more to life than just HbA1c?
4 What are the clinical outcomes associated with HbA1c? The Diabetes Control and Complications Trial
5 The DCCT 1,441 patients with type 1 diabetes Half the patients assigned to conventional treatment one or two insulin injections per day aim to remain asymptomatic Half the patients assigned to intensive treatment 3 or more injections per day aim for preprandial BG 3.9 to 6.7mmol/L Followed for a mean of 6.5 (0-9) years DCCT Group 1993;329:977-86
6 DCCT: Glucose in treatment groups
7 HbA1c (%) DCCT: HbA1c in treatment groups Intensive Conventional Yrear of Study
8 DCCT: Results Intensive treatment was associated with: 76% reduction in risk of retinopathy 39% reduction in risk of microalbuminuria 54% reduction in risk of albuminuria 60% reduction in risk of neuropathy DCCT Group 1993;329:977-86
9 DCCT: Risk of Microvascular Complications
10 DCCT: Risk of Severe Hypoglycaemia
11 UKPDS: Risk of Macro and Microvascular Complications UKPDS Group. BMJ 2000;321:405-
12 CVD after the DCCT 42% DCCT/EDIC Group. N Engl J Med 2005;353:
13 Playing the odds If I had a child develop type 1 diabetes tomorrow What are the chances they will remain complication-free for the rest of their life?
14 % Risk of Retinopathy progression in next year DCCT: risk of retinopathy progression HbA1c (%) HbA1c (mmol/mol)
15 Probability of retinopathy progression Cumulative risk HbA1c (%) HbA1c (mmol/mol) 1 year
16 Probability of retinopathy progression Cumulative risk HbA1c (%) HbA1c (mmol/mol) 1 year 5 years
17 Probability of retinopathy progression Cumulative risk HbA1c (%) HbA1c (mmol/mol) 1 year 5 years 10 years
18 Probability of retinopathy progression Cumulative risk HbA1c (%) HbA1c (mmol/mol) 1 year 5 years 10 years 20 years
19 Probability of retinopathy progression Cumulative risk HbA1c (%) HbA1c (mmol/mol) 1 year 5 years 10 years 20 years 30 years
20 Probability of retinopathy progression Cumulative risk HbA1c (%) HbA1c (mmol/mol) 1 year 5 years 10 years 20 years 30 years 40 years
21 Probability of retinopathy progression Cumulative risk HbA1c (%) HbA1c (mmol/mol) 1 year 5 years 10 years 20 years 30 years 40 years 50 years
22 Probability of retinopathy progression Playing the odds 19 years old HbA1c (%) HbA1c (mmol/mol) 1 year 5 years
23 50:50 odds of developing retinopathy HbA1c % mmol/mol Age (years)
24 HbA1c standardisation and clinical outcomes What are the clinical outcomes associated with HbA1c? How has standardisation improved the precision of outcomes? Could a HbA1c unit change worsen outcomes? Is there more to life than just HbA1c?
25 Sep-96 Jan-97 May-97 Aug-97 Nov-97 Mar-98 Jul-98 Nov-98 Mar-99 Juy-99 Jan-00 May-00 Sep-00 Jan-01 May-01 Sep-01 Mar-02 Jul-02 Nov-02 May-03 Sep-03 Jan-04 May-04 Sep-04 Jan-05 May-05 Overall CV (%) % DCCT aligned methods NGSP programme -Dec'96 Menarini Standardisation meeting - Sep '98 Interlaboratory variation HbA1c UK Consensus statement - Jan '00 IFCC standardisation adopted by manufacturers Jan '04 Sample 1 Sample 2 CV Trendline Date
26 50:50 odds of developing retinopathy HbA1c % mmol/mol Age (years)
27 50:50 odds of developing retinopathy HbA1c % mmol/mol Age (years)
28 50:50 odds of developing retinopathy HbA1c % mmol/mol Age 8% CV
29 50:50 odds of developing retinopathy HbA1c % mmol/mol Age 8% CV 24 (22 29) 26 (23 34) 30 (25 42) 36 (28 56) 48 (34 85) 73 (46 138) 129 (73 277)
30 50:50 odds of developing retinopathy HbA1c % mmol/mol Age 8% CV 24 (22 29) 26 (23 34) 30 (25 42) 36 (28 56) 48 (34 85) 73 (46 138) 129 (73 277) 3% CV
31 50:50 odds of developing retinopathy HbA1c % mmol/mol Age 8% CV 3% CV 24 (22 29) (23 27) 26 (23 34) (24 28) 30 (25 42) (27 33) 36 (28 56) (32 41) 48 (34 85) (41 58) 73 (46 138) (61 90) 129 (73 277) ( )
32 What about using HbA1c for diagnosis of type 2 diabetes?
33 WHO,
34 Sep-96 Jan-97 May-97 Aug-97 Nov-97 Mar-98 Jul-98 Nov-98 Mar-99 Juy-99 Jan-00 May-00 Sep-00 Jan-01 May-01 Sep-01 Mar-02 Jul-02 Nov-02 May-03 Sep-03 Jan-04 May-04 Sep-04 Jan-05 May-05 Overall CV (%) % DCCT aligned methods NGSP programme -Dec'96 Menarini Standardisation meeting - Sep '98 Interlaboratory variation HbA1c UK Consensus statement - Jan '00 IFCC standardisation adopted by manufacturers Jan '04 Sample 1 Sample 2 CV Trendline Date
35 Imprecision and diagnosis At 48mmol/mol (6.5%) threshold: 8% CV between-labcorresponds to 40 to 56mmol/mol (5.8% to 7.3%)
36 UKNEQAS HbA1c Aug 2014 SI (IFCC) value 46mmol/mol (6.3%) CV=5.6% 5.6% 6.9%
37 HbA1c standardisation and clinical outcomes What are the clinical outcomes associated with HbA1c? How has standardisation improved the precision of outcomes? Could a HbA1c unit change worsen outcomes? Is there more to life than just HbA1c?
38 Getting used to SI numbers DCCT IFCC (mmol/mol) 4% 20 5% 31 6% 42 7% 53 8% 64 9% 75 10% 86
39 Effect of method change on clinician HbA1c targets Hanas R. Diabetes Care 2002; 25:
40 Getting used to SI numbers DCCT IFCC (mmol/mol) 4% 20 5% 31 6% 42 7% 53 8% 64 9% 75 10% 86
41 Kilpatrick s Kludge minus 2 minus 2 DCCT 7% Eric Kilpatrick, ACB mailbase 30/1/08
42 Kilpatrick s Kludge minus 2 minus 2 DCCT -2 7% 5 Eric Kilpatrick, ACB mailbase 30/1/08
43 Kilpatrick s Kludge minus 2 minus 2 DCCT % 5 3 Eric Kilpatrick, ACB mailbase 30/1/08
44 Kilpatrick s Kludge minus 2 minus 2 DCCT -2-2 IFCC 7% mmol/mol Eric Kilpatrick, ACB mailbase 30/1/08
45 DCCT 4% 5% 6% 7% 8% 9% 10% Kilpatrick s Kludge
46 DCCT -2 4% 2 5% 3 6% 4 7% 5 8% 6 9% 7 10% 8 Kilpatrick s Kludge
47 DCCT % 2 0 5% 3 1 6% 4 2 7% 5 3 8% 6 4 9% % 8 6 Kilpatrick s Kludge
48 DCCT % 2 0 5% 3 1 6% 4 2 7% 5 3 8% 6 4 9% % 8 6 Kilpatrick s Kludge
49 DCCT % 20 5% 31 6% 42 7% 53 8% 64 9% 75 10% 86 Kilpatrick s Kludge
50 Kilpatrick s Kludge DCCT IFCC (mmol/mol) 4% 20 5% 31 6% 42 7% 53 8% 64 9% 75 10% 86
51 Transition to SI HbA1c units in the UK Pre-1 st June 2009 Only NGSP (%) units reported 1 st June st October 2011 Dual reporting of NGSP and SI units Post-1 st October 2011 Only SI (mmol/mol) reported
52 Aims To establish if HbA1c values in diabetes patients changed in the year after SI-only reporting was introduced in Hull, UK To determine if the HbA1c following a raised (>8%/64mmol/mol) result was different after the unit change
53 Monthly mean HbA1c (%) HbA1c before and after unit change
54 HbA1c before and after unit change Year before unit Year after unit change change All samples n p-value HbA1c (%) 7.5 (6.6,8.7) 7.5 (6.5,8.7) 0.34 (mmol/mol) 58 (49,72) 58(48,72) All data expressed as median (25 th, 75 th centiles)
55 Change in HbA1c following initial value>8% Year before unit change Year after unit change n p value HbA1c change (%) (mmol/mol) -0.2(-0.9,0.3) -2(10,3) -0.2(-0.8,0.3) -2 (9,3) 0.44 Days between HbA1c samples 99(64,147) 98(64,147) 0.45 Difference between 2 successive DCCT/SI values (before unit change) and 2 successive SI-only values (after unit change)
56 Why no difference??healthcare staff adapted better than anticipated?related to good educational material and/or the dual reporting period?having to take care because of the complete change in numbers?converting back to NGSP
57 Conclusions A move to SI HbA1c reporting did not lead to: Any marked short-term deterioration in glycemia A different HbA1c outcome in patients with initial poor glucose control.
58 HbA1c standardisation and clinical outcomes What are the clinical outcomes associated with HbA1c? How has standardisation improved the precision of outcomes? Could a HbA1c unit change worsen outcomes? Is there more to life than just HbA1c?
59 HbA1c (%) DCCT: HbA1c in treatment groups Intensive Conventional Yrear of Study
60 HbA1c and retinopathy risk in the DCCT HbA1c explained 96% of the difference in retinopathy risk between the treatment groups BUT HbA1c did not explain 96% of the retinopathy risk Diabetes 2008;57:
61 Understanding the DCCT Glycaemic exposure (A1C + duration of diabetes) explains 11% of the variation of DR risk in the DCCT Diabetes 2008;57:
62 Understanding the DCCT 89 so that other factors may presumably explain the remaining 89% of the variation in risk among subjects independent of A1C. Diabetes 2008;57:
63 What might explain the 89% of risk??genetic?environmental?other known vascular risk factors e.g. hypertension, hyperlipidaemia
64 HbA1c variability and complication risk in the DCCT Diabetes Care 31: , 2008
65 HbA1c variability and complication risk Type 1 diabetes Type 2 diabetes in the majority of studies, [HbA1c] variability was more predictive of adverse outcomes than mean HbA1c. Diabetes Care 2015;38:
66 HbA1c variability and complication risk Can we run people with high mean HbA1c values as long as they are stable? Would this mean they would be at the same risk of microvascular complications but less risk of hypoglycaemia? Might HbA1c variability become a new diagnostic target to aim for?
67 HbA1c standardisation and clinical outcomes What are the clinical outcomes associated with HbA1c? How has standardisation improved the precision of outcomes? Could a HbA1c unit change worsen outcomes? Is there more to life than just HbA1c?
68 Summary HbA1c has been shown to be a marker of vascular complication risk in type 1 and 2 diabetes Standardisation has allowed a large improvement in the clinical precision of the test, especially over longer periods of time Evidence to date is that changing HbA1c units as part of standardisation does not necessarily have a detrimental effect on patient care Glycaemia is only one factor in the development of diabetes complications
Charles Darwin University
Charles Darwin University Area-under-the-HbA1c-curve above the normal range and the prediction of microvascular outcomes an analysis of data from the Diabetes Control and Complications Trial Maple-Brown,
More informationType 2 Diabetes. Treat to: limit complications maintain quality of life Improve survival
Type 2 Diabetes Treat to: limit complications maintain quality of life Improve survival 1 Criteria for the diagnosis of diabetes 1. HbA1C 6.5% (rounded to 50mmol/mol). 2. FPG 7.0 mmol/l. 3. 2-h plasma
More informationUpdate on Diabetes. Ketan Dhatariya. Why it s Not Just About Glucose Lowering Any More. Consultant in Diabetes NNUH
Update on Diabetes Why it s Not Just About Glucose Lowering Any More Ketan Dhatariya Consultant in Diabetes NNUH The Story So Far.. DCCT Retinopathy Neuropathy Nephropathy Intensive glucose control in
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationEQAS. Hemoglobin Program (BC80) Cycle 12: December 2014 December 2015 Sample No: 1 Sample Date: 17 Dec 14. Exceptions. Customer Information
(BC80) : December 2014 December 20 Exceptions None at this time. Legend: No Warnings Missing Result Late Results < < > * Amended Result (per participant s request) News Customer Information Please refer
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationMicrovascular Complications in Diabetes:
Microvascular Complications in Diabetes: Perspectives on Glycemic Control to Prevent Microvascular Complications Discussion Outline: Glycemia and Microvascular Compliations Clinical Trials - A Brief History
More informationREVIEW Global standardisation of HbA 1c
Malaysian J Pathol 2008; 30(2) : 67 71 REVIEW Global standardisation of Leslie C LAI, FRCP, FRCPath Gleneagles Intan Medical Centre, Kuala Lumpur, Malaysia Abstract is used for assessing glycaemic control
More informationHypoglycaemia in the community
Hypoglycaemia in the community Using local data to monitor the quality of diabetes services Adrian R Scott 11 th April 2008 Sheffield Teaching Hospitals NHS Foundation Trust DCCT: the price of improved
More informationADAG Study Group Data Links A1C Levels with Empirically Measured Blood Glucose Values - New Treatment Guidelines Will Now be Needed
529638DSTXXX10.1177/1932296814529638Journal of Diabetes Science and TechnologyKlonoff research-article2014 Editorial ADAG Study Group Data Links A1C Levels with Empirically Measured Blood Glucose Values
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationNew Guidelines for the Diagnosis of Diabetes Mellitus
New Guidelines for the Diagnosis of Diabetes Mellitus Joely Straseski, PhD, DABCC, FACB Assistant Professor and Medical Director Endocrinology and Automated Core Laboratory University of Utah and ARUP
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meetings 1 st and 2 nd September 2016 - London and Leeds Prof Sunil
More informationState of the Art of HbA1c Measurement
State of the Art of HbA1c Measurement XXI Congreso Latinoamericano de Patologia Clinica Y XLII Congreso Mexicano de Patologia Clinica, Cancun October 2012 Randie R. Little, Ph.D. NGSP Network Laboratory
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationPolicy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus Version No. Changes Made Version of July 2018 V0.5 Changes made to the policy following patient engagement including: - the
More informationMoving to an A1C-Based Screening & Diagnosis of Diabetes. By Prof.M.Assy Diabetes&Endocrinology unit
Moving to an A1C-Based Screening & Diagnosis of Diabetes By Prof.M.Assy Diabetes&Endocrinology unit is the nonenzymatic glycated product of the hemoglobin beta-chain at the valine terminal residue. Clin
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationHbA1c variability and the risk of microvascular complications in type 1 diabetes: data from the DCCT
Diabetes Care Publish Ahead of Print, published online July 23, 2008 HbA1c variability and complications HbA1c variability and the risk of microvascular complications in type 1 diabetes: data from the
More informationMaintaining Quality in Laboratory Medicine. Glycated Haemoglobin Scheme Guide
Maintaining Quality in Laboratory Medicine Glycated Haemoglobin Scheme Guide Contents 1. Scheme Details and repertoire 1.1 Source Material and Serum Integrity 3 1.2 List of Analytes and Frequency of Distribution
More informationUniversity College Hospital. Blood glucose and HbA 1 c targets
University College Hospital Blood glucose and HbA 1 c targets Children & Young People s Diabetes Service The diabetes team at UCLH aims to help every child and young person with Type 1 Diabetes to safely
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationComplications of Diabetes: Screening and Prevention. Dr Martin McIntyre Consultant Physician Royal Alexandra Hospital Paisley
Complications of Diabetes: Screening and Prevention Dr Martin McIntyre Consultant Physician Royal Alexandra Hospital Paisley Diabetic Complications Microvascular: Retinopathy Nephropathy Neuropathy Macrovascular:
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationGlucose Control: Does it lower CV risk?
Glucose Control: Does it lower CV risk? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationImplementation of HbA1c as a Diagnostic Test in New Zealand
Implementation of HbA1c as a Diagnostic Test in New Zealand Chris Florkowski MD MRCP(UK) FRACP FRCPA FFSc Consultant in Chemical Pathology, Canterbury Health Laboratories Diabetes Physician, Christchurch
More informationCOMPARISON OF CATION EXCHAGE HPLC AND IMMUNOTURBIDIMETRIC METHOD FOR DETERMINATION OF HbA1c
D:\Biomedica Vol.27, Jul. Dec. 2011\Bio-1.Doc P. 161 165 (KC) IV COMPARISON OF CATION EXCHAGE HPLC AND IMMUNOTURBIDIMETRIC METHOD FOR DETERMINATION OF HbA1c FARZANA YASMEEN, ASIM MUMTAZ, SALEEM-UZ-ZAMAN
More informationInitiation of insulin adjustment for carbohydrate at onset of diabetes in children using a home-based education programme with a bolus calculator
Initiation of insulin adjustment for carbohydrate at onset of diabetes in children using a home-based education programme with a bolus calculator H Thom 1 BSc (Hons), Paediatric Diabetes Dietitian S Greene
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationWhat s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
More informationData from the Diabetes Control and Complications Trial
Pathophysiology/Complications O R I G I N A L A R T I C L E A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes Data from the Diabetes Control and Complications Trial ERIC S.
More informationHemoglobin A1c: Comparison of Pointe Scientific s 2-Part Direct Hemoglobin A1c with the Bio-Rad Variant II and the Tosoh G8
Hemoglobin A1c: Comparison of Pointe Scientific s 2-Part Direct Hemoglobin A1c with the Bio-Rad Variant II and the Tosoh G8 Joseph D. Artiss, Ph.D., FACB, Associate Professor of Pathology, Wayne State
More informationIn normal human erythrocytes,
Journal of the association of physicians of india JANUARY 2014 VOL. 62 9 Editorial HbA1c Result, Does it Depend Upon the Testing Methods? Samar Banerjee * * Dept of Medicine, Vivekananda Institute of Medical
More informationAdolescent renal and cardiovascular disease protection in type 1 diabetes AdDIT Study
Keystone, Colorado, July 2013 Practical Ways to Achieve Targets in Diabetes Care Adolescent renal and cardiovascular disease protection in type 1 diabetes AdDIT Study Professor David Dunger Department
More informationDiabetes Mellitus. Eiman Ali Basheir. Mob: /1/2019
Diabetes Mellitus Eiman Ali Basheir Mob: 091520385 27/1/2019 Learning Outcomes Discuss the WHO criteria for Diabetes Mellitus diagnosis Describe the steps taken to confirm diagnosis Interpret GTT. Discuss
More informationDiabetic & Complications. Dr. A K Viswanath Consultant Diabetologist
Diabetic & Complications Dr. A K Viswanath Consultant Diabetologist Outline Challenges in diabetes How do we fare? Diabetes complications Improving outcomes in diabetes Types of Diabetes Type-1 DM Genetic
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationFrom postseason injury analysis through pre-season screening risk management in the team setting
From postseason injury analysis through pre-season screening risk management in the team setting Roald Bahr MD PhD Professor & Chair Oslo Sports Trauma Research Center Norwegian School of Sport Sciences
More informationInternet Journal of Medical Update
Internet Journal of Medical Update 2010 July;5(2):8-14 Internet Journal of Medical Update Journal home page: http://www.akspublication.com/ijmu Original Work Treatment to targets in type 2 diabetics: analysis
More informationHbA1c enzymatic assay evaluation at AN academic
Peer reviewed ORIGINAL ARTICLE HbA1c enzymatic assay evaluation at AN academic laboratory B Phiri-Ramongane Mmed Chem Path, FCP Path(SA)-Chem Department of Chemical Pathology, Sefako Makgatho Health Sciences
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More informationThe Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial -- Revisited
Diabetes Publish Ahead of Print, published online January 25, 2008 The Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial -- Revisited
More informationDiabetes Diagnosis 2011 Does your patient have diabetes?
Diabetes Diagnosis 2011 Does your patient have diabetes? Dr Rick Cutfield Physician and Endocrinologist Waitemata District Health Board Mercy Specialist Centre Case 1: A 24 year old stockcar driver presents
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationThe Non-inferiority Margin in Diabetes Trials
The non-inferioirty margin in diabetes trials 20NOV2008 The Non-inferiority Margin in Diabetes Trials Lars Endahl Biostatistics, Novo Nordisk The non-inferioirty margin in diabetes trials 20NOV2008 Slide
More informationDiabetic Retinopathy
Diabetic Retinopathy Overview This presentation covers the following topics: Definitions Epidemiology of diabetic retinopathy Evidence for public health approaches Screening for diabetic retinopathy Health
More informationCost-Effectiveness of Lung Volume Reduction Surgery
Cost-Effectiveness of Lung Volume Reduction Surgery The Health Industry Forum October 24, 2007 - Washington DC The National Emphysema Treatment Trial National Emphysema Treatment Trial (NETT) Multicenter,
More informationFlu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 3: January 14 to January 2, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More informationNational Institute for Health and Care Excellence. Type 2 diabetes. Stakeholder Comments Draft Guideline
National Institute for Health and Care Excellence Type 2 diabetes Stakeholder Comments Draft Guideline NOTE: NICE is unable to accept comments from non-registered organisations or individuals. If you wish
More informationLong-Term Care Updates
Long-Term Care Updates January 2019 By Kristina Nikl, PharmD Several recent studies evaluating the management of diabetes in older adults have concluded that 25-52% of elderly patients are currently being
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationNICE Indicator Programme. Consultation on proposed amendments to current QOF indicators
NICE Indicator Programme Consultation on proposed amendments to current QOF s Consultation dates: 18 July to 1 August 2018 This document outlines proposed amendments to a small number of QOF s in the diabetes
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationABCD position statement on haemoglobin A1c for the diagnosis of diabetes
ABCD position statement on haemoglobin A1c for the diagnosis of diabetes ES Kilpatrick, PH Winocour*; on behalf of the Association of British Clinical Diabetologists (ABCD). Endorsed by the Association
More informationFlu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 4: January 21 to January 27, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More informationDr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead
Dr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead Today s Presentation HbA1c & diagnosing Diabetes What is Impaired Glucose & IGR? Implications
More informationType 2 Diabetes: Screening and Prevention. Updating the Scottish Needs Assessment Programme Report on. Recommendations
Scottish Updating Public the Scottish Health Needs Network Assessment (ScotPHN) Programme Report on Type 2 Diabetes: Screening and Prevention Updating the Scottish Needs Assessment Programme Report on
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationFGSZ Zrt. from 28 February 2019 till 29 February 2020 AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS
AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS FIRM CAPACITY - First Monday of July 01.06.2019* 01.07.2019 07:00 01.10.2019 04:00 01.10.2020 04:00 2019/2020 01.10.2020 04:00 01.10.2021
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationDCCT Diabetes Control & Complications Trial
DCCT Diabetes Control & Complications Trial A. Vinik MD, PhD, FCP, MACP, FACE, Καθηγητής και Αντιπρόεδρος για την Έρευνα, Ιατρική Σχολή Ανατολικής Βιρτζίνια, Κέντρο Ενδοκρινολογικών και Μεταβολικών Νοσημάτων,
More informationNHS Greater Glasgow & Clyde Managed Clinical Network for Diabetes
Guidelines for the Diagnosis of Diabetes Mellitus NHS Greater Glasgow & Clyde Managed Clinical Network for Diabetes Lead Authors: Dr Brian Kennon, Dr David Carty June 2015 Review due: December 2016 Diagnosis
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationGlycemic Control Patterns and Kidney Disease Progression among Primary Care Patients with Diabetes Mellitus
ORIGINAL RESEARCH Glycemic Control Patterns and Kidney Disease Progression among Primary Care Patients with Diabetes Mellitus Doyle M. Cummings, PharmD, Lars C. Larsen, MD, Lisa Doherty, MD, MPH, C. Suzanne
More informationPrimary Care Commission Study Visit. 26 March 2015
Primary Care Commission Study Visit 26 March 2015 1 Agenda 1. How we got to where we are? 2. Suffolk GP Federation 3. North East Essex diabetes service 4. Working at scale issues and challenges 2 1. How
More informationHIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE
HIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE Site C Youth clinic HIV care pathway DAY 1 Test HIV + PIMA point of care CD4 count in in 3-5 days initiation + in session 3 session 4 1 month Youth Club
More informationCardiovascular Diabetology. Open Access ORIGINAL INVESTIGATION. C. R. L. Cardoso 1, N. C. Leite 1, C. B. M. Moram 2 and G. F.
https://doi.org/10.1186/s12933-018-0677-0 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Long term visit to visit glycemic variability as predictor of micro and macrovascular complications
More informationOverview of diabetes complications
Overview of diabetes complications Programme Diabetes control and complications RAGEs Hypo Awareness The foot attack Identifying ulceration and sepsis Managing the complications and reducing morbidity
More informationOverview of the Radiation Exposure Doses of the Workers at Fukushima Daiichi Nuclear Power Station
Click here for the corrections made < Reference > December 3, 212 Tokyo Electric Power Company Overview of the Radiation Exposure Doses of the Workers at Fukushima Daiichi Nuclear Power Station * As of
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationHaemoglobin A 1c in the diagnosis and monitoring of diabetes mellitus
See Review, p 983 Correspondence to: Professor Eric S Kilpatrick, Department of Clinical Biochemistry, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ, UK; Eric.Kilpatrick@hey. nhs.uk Accepted 26 February
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationPLEASE REMEMBER TO BRING TO EACH APPOINTMENT
PLEASE REMEMBER TO BRING TO EACH APPOINTMENT Conversion table for HbA1c% to mmol/mol Old DCCT aligned HbA1c(%) New IFCC HbA1c (mmol/mol) 4.0 20 5.0 31 6.0 42 6.5 48 7.0 53 7.5 59 8.0 64 9.0 75 10.0 86
More informationHbA1c and Diabetes. Steven Weier Senior Lecturer School of Biomedical Sciences Faculty of Health QUT. CRICOS No J
HbA1c and Diabetes Steven Weier Senior Lecturer School of Biomedical Sciences Faculty of Health QUT Queensland University of Technology History of HbA1c 1966: Holmquist and Schroeder identify five subtypes
More informationDiabetes Prevention & Management of Complications
Diabetes Prevention & Management of Complications Dr Ketan Dhatariya Consultant in Diabetes and Endocrinology NNUH The Planet is Changing IFCC (mmol/mol) = (current value (%) * 10.93) - 23.50 (reported
More informationDiabetes outcomes Keystone 17 July 2014
Diabetes outcomes Keystone 17 July 214 How diabetes outcomes have changed over the past 3 years JBN: 194,119.11 Date of Prep: June 214 Professor Philip Home Newcastle University How diabetes outcomes have
More information1. What s the point of a network the case for research? 2. How to use CSII effectively
1. What s the point of a network the case for research? 2. How to use CSII effectively John Pickup King s College London Faculty of Medicine Guy s Hospital, London What should an insulin pump network do?
More informationReferral to Adult Diabetes Specialist Services
Referral to Adult Diabetes Services Aim(s) and objective(s) To ensure that those people with Diabetes Mellitus (DM) who live within Lanarkshire are appropriately referred to the Diabetes Service (Consultant,
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More information04-Sep-17. INERTIA a failure to initiate or modify treatment in a timely manner in people whose health is likely to improve with this modification
PROF MERLIN THOMAS DIAttitude Study INERTIA a failure to initiate or modify treatment in a timely manner in people whose health is likely to improve with this modification 13% immediately 41% of patients
More information